Inhibitory effect of valproic acid on bladder cancer in combination with chemotherapeutic agents in vitro and in vivo

Oncology Letters

Volumn 6, Issue 5, 2013, Pages 1492-1498

  Wang, Degui ^a   Jing, Yuhong ^a   Ouyang, Siwei ^a   Liu, Bei ^a   Zhu, Tianyuan ^a   Niu, Haitao ^c   Tian, Yingxia ^b  

^a LANZHOU UNIVERSITY   (China)

^b Institute of Gansu Medical Science Research   (China)

^c QINGDAO UNIVERSITY   (China)

Author keywords

Apoptosis; Bladder cancer; Combination; Therapy; Valproic acid

Indexed keywords

CISPLATIN; DOXORUBICIN; HISTONE H3; MITOMYCIN; SURVIVIN; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER INHIBITION; CELL PROLIFERATION; CELL STRUCTURE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; INCIDENCE; NONHUMAN; PROTEIN EXPRESSION; RAT; TUMOR GROWTH; WESTERN BLOTTING;

EID: 84884476220     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1565     Document Type: Article

References (18)

1. Wallerand H, Bernhard JC, Culine S, et al: Targeted therapies in non-muscle-invasive bladder cancer according to the signaling pathways. Urol Oncol 29: 4-11, 2011.
2. Ai T, Cui H and Chen L: Multi-targeted histone deacetylase inhibitors in cancer therapy. Curr Med Chem 19: 475-487, 2012.
3. Ouaïssi M, Giger U, Sielezneff I, Pirrò N, Sastre B and Ouaissi A: Rationale for possible targeting of histone deacetylase signaling in cancer diseases with a special reference to pancreatic cancer. J Biomed Biotechnol 2011: 315939, 2011.
4. Mottet D and Castronovo V: Histone deacetylases: anti-angiogenic targets in cancer therapy. Curr Cancer Drug Targets10: 898-913, 2010.
5. Botrugno OA, Santoro F and Minucci S: Histone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer. Cancer Lett 280: 134-144, 2009.
6. Chapman A, Keane PE, Meldrum BS, Simiand J and VernieresJC: Mechanism of anticonvulsant action of valproate. Prog Neurobiol 19: 315-359, 1982.
7. Byler TK, Leocadio D, Shapiro O, et al: Valproic acid decreases urothelial cancer cell proliferation and induces thrombospondin-1 expression. BMC Urol 12: 21, 2012.
8. Chen X, Wong JY, Wong P and Radany EH: Low-dose valproic acid enhances radiosensitivity of prostate cancer through acetylated p53-dependent modulation of mitochondrial membrane potential and apoptosis. Mol Cancer Res 9: 448-461, 2011.
9. Cinatl J Jr, Kotchetkov R, Blaheta R, Driever PH, Vogel JU and CinatlJ: Induction of differentiation and suppression of malignant phenotype of human neuroblastoma BE(2)-C cells by valproic acid: enhancement by combination with interferon-alpha. Int JOncol 20: 97-106, 2002.
10. Kortenhorst MS, Isharwal S, van Diest PJ, et al: Valproic acid causes dose-and time-dependent changes in nuclear structure in prostate cancer cells in vitro and in vivo. Mol Cancer Ther 8: 802-808, 2009.
11. Xu SP, Sun GP, Shen YX, Wei W, Peng WR and WangH: Antiproliferation and apoptosis induction of paeonol in HepG2 cells. World J Gastroenterol 13: 250-256, 2007.
12. Catalano MG, Fortunati N, Pugliese M, Costantino L, Poli R, Bosco O and Boccuzzi G: Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells. J Clin Endocrinol Metab90: 1383-1389, 2005.
13. Kaiser M, Zavrski I, Sterz J, et al: The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma. Haematologica91: 248-251, 2006.
14. Guindalini RS, Mathias Machado MC and Garicochea B: Monitoring survivin expression in cancer: implications for prognosis and therapy. Mol Diagn Ther: Aug 3, 2013 (Epub ahead of print).
15. Wang D, Siwei O, Tian Y, Yang Y, Bo L, Liu X and Song Y: Intravesical treatment with vorinostat can prevent tumor progression in MNU induced bladder cancer. J Cancer Ther4: 1-6, 2013.
16. Qi H and Ratnam M: Synergistic induction of folate receptor beta by all-trans retinoic acid and histone deacetylase inhibitors in acute myelogenous leukemia cells: mechanism and utility in enhancing selective growth inhibition by antifolates. Cancer Res66: 5875-5882, 2006.
17. Sanchez-Gonzalez B, Yang H, Bueso-Ramos C, et al: Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor. Blood 108: 1174-1182, 2006.
18. Kuendgen A, Schmid M, Schlenk R, et al: The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer 106: 112-119, 2006.